of cartilage oligomeric matrix protein causes dilated cardiomyopathy.
B
asic cardiovascular research in China has developed dramatically during the last decade but faces unique challenges especially to improve quality and impact. In this viewpoint, we analyzed the causes that have contributed to such accelerated research activity in the cardiovascular field and discuss ways to deal with the challenges.
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in China presenting rapidly evolving public health and economic burdens. 1 China recognizes the need to develop a modern and optimized medical care system that includes cutting edge translational biomedical research to target CVD as a fundamental ingredient. Rapidly growing financial support from government sources has fueled quantum increases in scientific output of cardiovascular basic research in China during the past decade. However, China still faces significant challenges to improve the efficiency, quality, and impact of such research, as well as to effectively address the prevention and treatment of CVD.
Chinese Cardiovascular Basic Research Output
In parallel with China's elevation to the world's second largest economy, scientific publications in cardiovascular research (CVR) also achieved remarkable growth. Figure 1B) . These data confirm a major and continuing increase in scientific contributions from Chinese scientists to the global field of CVR. Noteworthily, although the academic impact of Chinese publications, reflected by highly cited papers, during the past 10 years has been significantly enhanced, it does not match the exceptional growth in total publications.
Intellectual property, filed and issued patents represent another measure of scientific output and innovation. On the basis of the analysis of database from Dialog Innography by the Shanghai Information Center for Life Sciences of the CAS, there were totally 19 112 disclosed patents from China in the field of CVR during 2006 to 2015, representing 16% of the world total in 2006 and 31% in 2015. This ranks Chinese new patents as second in the world for 2015. However, in terms of Patent Cooperation Treaty patents in the cardiovascular area, China only contributed 1% of the world total in 2006 and 3% in 2015, with ninth rank globally. These analyses confirm the rapid increase in quantity but not necessarily quality of CVR scientific output in China. To improve quality and impact, the Chinese research culture needs to change to become more focused on original, innovative, and high-risk, high-gain/impact research. 2 As a result, the number of publications on vascular smooth muscle cells, atherosclerosis, and microRNA has significantly increased. 3 Some important pioneering breakthroughs in basic translational research are attributed to the increased and targeted funding, for example, it was first reported by Chinese scientists that the coronary artery is derived from endocardium 4, 5 ; muscle-specific mitsugumin 53 acts as a primary component of cardiac ischemic preconditioning and critically contributes to cardiac diabetic cardiomyopathy via regulating fatty acid metabolism [6] [7] [8] ; endothelial function is improved by dietary capsaicin through activating the transient receptor potential vanilloid 9, 10 ; and consumption of spicy foods is related to a reduced risk of mortality because of ischemic heart diseases. Although the rapid increase of government investment has brought a robust increase in the output of CVR, the funding is still not appropriately in line with the rapid development of the national Gross Domestic Product, growing aging population, and the urgent health needs of patients with CVD. To continue improvement of the quality and impact of Chinese cardiovascular science and promote translational research and precision therapy, a continuing increase of investment from government, including the central and local governmental agencies, in this area is imperative to ensure high-quality research with global impact. In addition, the financial support from nongovernment sources needs to be energetically developed. This needs to be supported and guided at least in part by the central or local governments to substantially increase private sector initiatives to develop innovative research programs and recruit and retain talents, by integrating government, clinical and private sector resources, and platforms. Figure 1D ). This major transition in the support for talents helps to foster and retain outstanding researchers in this field and especially benefits the development of young researchers. Until now, a total of 25 young scholars in the field of CVR were supported by NSFC for Distinguished Young Scholars Program. They all conducted creative researches and grew up as outstanding academic leaders in the forefront of clinical and basic research in CVR and made important contribution to the development of CVR in China.
Funding Roles

Researcher Roles
Meanwhile, more highly motivated and talented MS and PhD students as well as young researchers are involved in CVR. As a result, the base of cardiovascular researchers in China significantly increased during the past 10 years, for example, membership in the China Section of the International Society for Heart Research increased from 289 in 2006 to 1140 in 2015 (provided by the China Section of International Society for Heart Research). However, the evolving base and capacity of Chinese cardiovascular researchers do not adequately meet the urgent need for reducing the CVD risk. The world-class academic leaders, as well as highly talented and experienced research leaders, need to be fostered. Moreover, a stronger funding support to postdoctoral scientists, and training for researchers, including principal investigators at all stages of careers, as well as the technicians, are needed. In addition, evaluations for faculty recruitment and scientific performance needs to involve broader assessment mechanisms to include research productivity-based global relevance as well as scientific quality rather than simply counting the publication number or impact factors as is currently practiced at most Chinese institutions. Furthermore, a more productive and efficient research environment needs to be fostered by increasing global competition.
Cooperation Roles
Increased domestic and international cooperation, founded by NSFC and Chinese Ministry of Science and Technology, is contributing importantly to the rapid growth of output and impact of CVR. For example, NSFC increased funding for the International Cooperation Program from 1.03 million RMB in 2006 to 8.81 million RMB in 2015 ( Figure 1C and 1D ) and funded 15 Key International Cooperation Programs of CVR in the field of epigenetics, metabolomics, and stem cells in the past 5 years. Although most of these are still underway, some encouraging progress has already been made. For example, the researcher from Peking University collaborated with the researcher from University of London and revealed a novel molecular mechanism of vascular injury and repair. 13, 14 The success of domestic and international collaborations is exemplified by the increased incidence of highly cited collaborative papers during the past decade: collaborative highly cited papers increased from 0% in 2006 to 70% in 2015 (data were provided by the Shanghai Information Center for Life Sciences of CAS based on the Essential Science Indicators database). However, it is still necessary to further strengthen the relationship with the top-tier universities and institute globally and promote deeper and tighter domestic and international collaborations by sharing knowledge, facilities, and resources including scientific data and animal models. One specific and practical initiative to promote this would be to remove the barrier of authorship contribution by reforming the assessment system from assigning credit for each article solely to author(s) with first institute into a more appropriate way to recognize the contributions of all authors.
In conclusion, the increased government investment in CVR during the past decade has supported a remarkable transition of Chinese cardiovascular basic research productivity that is characterized by a surge in the volume of publications but moderate relative improvement in overall quality. Global research impact still lags behind publication quantity. To deal with the rapidly expanding challenges of CVD, the research model as it applies to the Chinese situation needs to be further developed and fine-tuned. First, a clinically driven, basic, and translational research model should be developed and implemented. Second, more emphasis needs to be given to develop, expand, and validate Traditional Chinese Medicine especially as it applies to the prevention and treatment of CVD. Third, cross-discipline integration and collaboration need to be emphasized. To implement these changes and ensure growth, China needs to increase funding for CVR even more, expand the base of researchers, and improve research environments as well as support system to favor excellence and innovation. In addition, more CVR centers and key laboratories need to be established to promote integrative and collaborative CVR at the levels of basic, translational, and clinical studied and developmental pharmacology research. Communication and collaboration between basic scientists with physicians need to be closer and deeper; the government and institutes need to develop efficient mechanisms and platforms to promote the collaboration between basic scientists and physicians. These efforts will be essential to continue the growth of Chinese CVD research, align it with the overall economic growth, and develop new strategies that are so urgently needed to fight against the growing threat of CVD to the people of China.
